Clearline Capital LP Increases Position in Teva Pharmaceutical Industries Ltd. $TEVA

Clearline Capital LP boosted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 55.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,098,786 shares of the company’s stock after acquiring an additional 392,674 shares during the quarter. Teva Pharmaceutical Industries accounts for approximately 1.0% of Clearline Capital LP’s portfolio, making the stock its 14th largest holding. Clearline Capital LP’s holdings in Teva Pharmaceutical Industries were worth $22,195,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Menora Mivtachim Holdings LTD. lifted its stake in Teva Pharmaceutical Industries by 31.9% during the second quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock worth $645,148,000 after purchasing an additional 9,303,978 shares during the last quarter. Soundwatch Capital LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at about $143,533,000. Wellington Management Group LLP lifted its position in Teva Pharmaceutical Industries by 39,228.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after buying an additional 6,878,304 shares during the last quarter. Maverick Capital Ltd. lifted its position in Teva Pharmaceutical Industries by 14,351.6% in the 2nd quarter. Maverick Capital Ltd. now owns 4,377,690 shares of the company’s stock worth $73,370,000 after buying an additional 4,347,398 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. boosted its stake in Teva Pharmaceutical Industries by 12.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after buying an additional 4,306,363 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 14,150 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $448,130.50. Following the completion of the transaction, the insider owned 6,774 shares of the company’s stock, valued at $214,532.58. This represents a 67.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Christine Fox sold 7,924 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $250,953.08. Following the completion of the sale, the executive vice president owned 84,905 shares of the company’s stock, valued at approximately $2,688,941.35. This trade represents a 8.54% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 948,499 shares of company stock valued at $30,897,071 in the last quarter. 0.49% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have commented on TEVA. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. The Goldman Sachs Group increased their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. Jefferies Financial Group boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. JPMorgan Chase & Co. upped their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

Teva Pharmaceutical Industries Stock Down 2.6%

Shares of NYSE TEVA opened at $28.54 on Friday. The firm’s fifty day moving average is $32.91 and its 200 day moving average is $26.68. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $37.35. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The company has a market cap of $32.81 billion, a price-to-earnings ratio of 23.78, a PEG ratio of 9.56 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.31. The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.